Treating Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) With Dasatinib
Treating Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) With Dasatinib PCR-Monitoring, Adherence, Quality of Life, Therapy Satisfaction
Sponsor: Onco Medical Consult GmbH
Listed as NCT02348957, this observational or N/A phase trial focuses on Myeloid Leukemia, Chronic, Chronic-Phase and remains completed. Sponsored by Onco Medical Consult GmbH, it has been updated 12 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Aug 2019 — Jan 2021 [monthly]
Completed
Status: Active Not Recruiting → Completed
▶ Show 7 earlier versions
-
Apr 2019 — Aug 2019 [monthly]
Active Not Recruiting
-
Jul 2018 — Apr 2019 [monthly]
Active Not Recruiting
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Active Not Recruiting
Phase: NA → None
-
Nov 2017 — Apr 2018 [monthly]
Active Not Recruiting NA
-
May 2017 — Nov 2017 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — May 2017 [monthly]
Recruiting NA
First recorded
Oct 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Onco Medical Consult GmbH
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Altötting, Germany, Arnsberg, Germany, Aschaffenburg, Germany, Augsburg, Germany, Bad Soden am Taunus, Germany, Bamberg, Germany, Bautzen, Germany, Bayreuth, Germany, Bergisch Gladbach, Germany, Berlin, Germany and 45 more location s